Bioplastics maker Danimer Scientific Holdings LLC has reached the end of the line.
The firm filed for Chapter 11 bankruptcy protection on March 18 in U.S. Bankruptcy Court in Wilmington, Del. Danimer officials said in a court filing that the firm "will immediately commence an orderly and value-maximizing wind-down of their businesses … [and] will use their time in Chapter 11 to market a sale or sales of all or substantially all of their assets."
Officials with Danimer in Bainbridge, Ga., could not be reached for comment. The firm operates a polylactic acid (PLA) resin plant there with up to 25 million pounds of annual production capacity. Danimer also operates a plant with annual polyhydroxyalkanoate (PHA) capacity of 55 million pounds in Winchester, Ky.
Danimer has assets valued at $622.5 million and debts of $449.5 million, according to a court filing. The debt amount includes $216.7 million in unsecured debt to U.S. Bank. Danimer's list of debts includes $192,000 to Mitsubishi Chemical, $157,000 to BASF Corp. and almost $100,000 to Total Corbion PLA.
In the first nine months of 2024, Danimer posted sales of $26.5 million, down 26 percent vs. that same period in 2023. The firm posted a nine-month loss of $56.7 million after losing $94.6 million in the year-ago period.
These results have sent Danimer's per-share stock price plummeting from almost $52 on March 20, 2024, to 35 cents in early trading March 19.
Market veteran Conor Carlin said he wasn't surprised by Danimer's bankruptcy filing.
"Despite the environmental benefits of PHA, including its biodegradability in both soil and marine environments, the technology faces persistent hurdles," he said in an email. Those hurdles include high production costs, limited scaling efficiencies and competition from lower-cost fossil-based and bio-based polymers such as PLA and bio-PET, he added.
Carlin, president of consulting firm Clefs Advisory LLC in Boston, also said the bankruptcy "is another example of just how difficult it is to achieve the yields and scale required to compete against incumbents."
"Choosing the public [stock] route was fraught with challenges and has proven to lead to significant losses for investors, which only makes the next effort to scale bioplastics more difficult," he added.